Electra Therapeutics, Inc. (NASDAQ:ETRA - Free Report) - Research analysts at HC Wainwright decreased their FY2026 EPS estimates for shares of Electra Therapeutics in a research note issued on Monday, November 16th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings of ($5.64) per share for the year, down from their prior estimate of ($3.17). HC Wainwright currently has a "Buy" rating and a $30.00 price target on the stock. The consensus estimate for Electra Therapeutics' current full-year earnings is ($3.45) per share. HC Wainwright also issued estimates for Electra Therapeutics' Q4 2026 earnings at ($0.48) EPS, Q1 2027 earnings at ($0.52) EPS, Q2 2027 earnings at ($0.58) EPS, Q3 2027 earnings at ($0.62) EPS, Q4 2027 earnings at ($0.68) EPS and FY2027 earnings at ($2.41) EPS.
ETRA has been the topic of several other reports. TD Cowen began coverage on Electra Therapeutics in a research report on Tuesday, October 13th. They issued a "buy" rating on the stock. JPMorgan Chase & Co. initiated coverage on Electra Therapeutics in a research report on Thursday, October 22nd. They set an "overweight" rating and a $36.00 target price for the company. Zacks Research raised Electra Therapeutics to a "hold" rating in a research note on Wednesday, October 14th. Evercore initiated coverage on Electra Therapeutics in a research note on Tuesday, October 13th. They set an "outperform" rating and a $36.00 target price on the stock. Finally, Cantor Fitzgerald initiated coverage on Electra Therapeutics in a report on Tuesday, October 13th. They issued an "overweight" rating on the stock. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has issued a Hold rating to the company's stock. According to MarketBeat, Electra Therapeutics has a consensus rating of "Buy" and a consensus price target of $33.50.
Check Out Our Latest Research Report on ETRA
Electra Therapeutics Trading Up 0.5%
NASDAQ:ETRA opened at $8.35 on Wednesday. The firm's 50-day simple moving average is $9.51. Electra Therapeutics has a 52 week low of $6.86 and a 52 week high of $15.50.
Electra Therapeutics (NASDAQ:ETRA - Get Free Report) last issued its earnings results on Thursday, November 12th. The company reported ($3.47) earnings per share for the quarter, missing the consensus estimate of ($1.76) by ($1.71).
Insider Buying and Selling at Electra Therapeutics
In related news, Director Carl L. Gordon purchased 1,333,333 shares of Electra Therapeutics stock in a transaction on Monday, September 21st. The shares were bought at an average cost of $15.00 per share, for a total transaction of $19,999,995.00. Following the acquisition, the director owned 5,126,891 shares in the company, valued at approximately $76,903,365. The trade was a 35.15% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Orbimed Advisors Llc purchased 1,333,333 shares of the firm's stock in a transaction on Monday, September 21st. The stock was bought at an average price of $15.00 per share, for a total transaction of $19,999,995.00. Following the purchase, the director owned 5,126,891 shares in the company, valued at approximately $76,903,365. This represents a 35.15% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have purchased 3,796,040 shares of company stock valued at $48,699,065 over the last ninety days.
Institutional Inflows and Outflows
A number of institutional investors have recently made changes to their positions in the company. RA Capital Management L.P. bought a new position in Electra Therapeutics during the third quarter valued at $19,046,000. Soleus Capital Management L.P. purchased a new position in shares of Electra Therapeutics in the 3rd quarter worth $2,812,000. Integral Health Asset Management LLC bought a new stake in shares of Electra Therapeutics in the 3rd quarter worth about $2,250,000. Finally, Goldman Sachs Group Inc. bought a new stake in shares of Electra Therapeutics in the 3rd quarter worth about $1,465,000.
Electra Therapeutics Company Profile
(
Get Free Report)
Electra Therapeutics, Inc. NASDAQ: ETRA is a clinical-stage biotechnology company focused on developing antibody-based medicines for diseases driven by abnormal immune-cell activity. The company's approach is designed to selectively eliminate or modulate disease-causing immune cells while preserving healthy immune function. Electra's lead investigational product is ELA026, an antibody targeting SIRPα, a protein involved in immune-cell signaling. The company is evaluating ELA026 in immune-mediated diseases, including systemic sclerosis and other conditions in which macrophages and related immune cells may contribute to disease progression.
Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Electra Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Electra Therapeutics wasn't on the list.
While Electra Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.